Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

BACKGROUND: Antibody-drug conjugate (ADC) construction poses numerous challenges that limit clinical progress. In particular, common bioconjugation methods afford minimal control over the site of drug coupling to antibodies. Here, such difficulties are overcome through re-bridging of the inter-chain...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Greene, Michelle K., Chen, Ting, Robinson, Eifion, Straubinger, Ninfa L., Minx, Charlene, Chan, Darren K. W., Wang, Jun, Burrows, James F., Van Schaeybroeck, Sandra, Baker, James R., Caddick, Stephen, Longley, Daniel B., Mager, Donald E., Straubinger, Robert M., Chudasama, Vijay, Scott, Christopher J.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653048/
https://ncbi.nlm.nih.gov/pubmed/32913288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01046-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items